Veena Patil, MD
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1922268580
Payments from drug & device makers
Across 253 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$891
- Lilly USA, LLC$524
- Boehringer Ingelheim$475
- Xeris Pharmaceuticals, Inc.$328
- IBSA Pharma Inc.$294
- Novo Nordisk$277
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,81799%
- Education$120%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 51 | $891 |
| Lilly USA, LLC | 24 | $524 |
| Boehringer Ingelheim | 26 | $475 |
| Xeris Pharmaceuticals, Inc. | 17 | $328 |
| IBSA Pharma Inc. | 21 | $294 |
| Novo Nordisk | 15 | $277 |
| AstraZeneca(2 entities) | 8 | $274 |
| Corcept Therapeutics | 13 | $266 |
| Amneal Pharmaceuticals LLC | 12 | $229 |
| Amgen | 9 | $191 |
| Abbott | 9 | $147 |
| Medtronic(2 entities) | 6 | $113 |
| Insulet Corporation | 6 | $112 |
| Merck | 5 | $90 |
| Mannkind Corporation | 3 | $90 |
| Bayer | 4 | $87 |
| Amarin Pharma, Inc. | 3 | $49 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| AbbVie | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $37 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Novartis | 2 | $36 |
| Tolmar, Inc. | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Chiesi USA, Inc. | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| GSK | 1 | $26 |
| Almatica Pharma LLC | 1 | $25 |
| Cequr Corporation | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Valeritas, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANDEXXA$100
How this compares
$4,889 in reported general payments places this provider in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $446,402 |
| MounjaroTirzepatide | 89 | $129,717 |
| JardianceEmpagliflozin | 90 | $123,957 |
| FarxigaDapagliflozin Propanediol | 55 | $77,073 |
| Humulin R U-500Insulin Regular, Human | 30 | $67,062 |
| TrulicityDulaglutide | 32 | $66,789 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $66,658 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $64,351 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $60,761 |
| Humalog Kwikpen U-200Insulin Lispro | 23 | $42,145 |
| JanuviaSitagliptin Phosphate | 33 | $41,124 |
| Repatha SureclickEvolocumab | 19 | $26,330 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $26,006 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $25,853 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $22,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $277 | $472,139268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog | $524 | $222,032161 claims |
| Boehringer IngelheimJardiance | $475 | $123,95790 claims |
| AstraZenecaFarxiga | $274 | $77,07355 claims |
| MerckJanuvia, Janumet Xr | $90 | $53,89453 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $891 | $25,85319 claims |
| AbbVieSynthroid | $40 | $7,22161 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $229 | $1,681176 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Orlando
- Richard PratleyOrlando$9.2M
- Steven SmithOrlando$7.9M
- Tina ThethiOrlando$3.8M
- Damon TantonOrlando$1.2M
- Hanford YauOrlando$489K
- Jose MandryOcoee$9.1M
- Barry HorowitzWest Palm Beach$7.1M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.